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ABSTRACT 
Introduction: 
             Platelets play an important role  in the pathogenesis of 
atherosclerosis and coronary artery disease.  Larger platelets are more active 
and facilitates the thrombus formation over the atherosclerotic plaque and 
subsequent acute coronary events. In this study an attempt is made to find out 
the significance of  mean platelet volume in acute coronary syndrome. 
Materials and Methods:  
  Study groups comprised of 111 subjects  which included 45 
patients with myocardial infarction , 41 patients with unstable angina and 25 
control group. Blood sample was taken at the time of admission and sent for 
mean platelet volume analysis. Statistical analysis was made through”one way 
variance analysis(ANOVA)” , post-hoc Tukey HSD and bonferroni method. 
Association of MPV with selected risk factors of  ACS was also studied along 
with short term outcome in MI. 
Observations and Results: 
  MPV in MI group(9.84±0.67fl) was significantly higher when 
 compared to Unstable angina (9.07±0.77fl) and control groups(6.85±0.73fl). 
MPV in Unstable angina group were also significantly higher when compared 
to control groups. MPV was significantly higher in hypertensives 
(9.42±1.03fl)when compared to non hypertensives(8.43±1.44fl). MPV was 
found to be significantly higher in those with lower ejection fraction  in MI 
groups. MPV was also significantly higher in those who died in MI 
groups(10.53±0.35fl). The sensitivity and specificity of MPV when compared to 
Trop t in detecting MI was 91.11% and 62.12% respectively and on ROC curve 
analysis 8.8fl was the cut off range . 
Conclusions: 
          Mean platelet volume was found to be  in the high normal range in 
those with acute coronary syndrome. It was found to predict the mortality and 
ejection fraction in MI. So MPV is a useful  diagnostic tool in detecting acute 
coronary events and can predict the complications along with other parameters. 
Key words:  
Acute coronary syndrome, Mean platelet volume 
Abbreviations: ACS- acute coronary syndrome, MPV- mean platelet volume, 
MI- myocardial infarction 
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                                         INTRODUCTION 
 
Acute coronary syndromes are a spectrum of ischemic myocardial events that 
range from unstable angina to non- ST elevation MI and ST-elevation 
myocardial infarction. They have a common end result; acute myocardial 
ischemia which predisposes the heart to cardiac death and myonecrosis. Despite 
the impressive strides in diagnosis and  management  in recent years, acute 
coronary syndrome (ACS) is still one of the  most important  cause of  
morbidity and mortality.  
                                           Major  risk factors  implicated in  coronary artery 
disease are  mainly age,  history of coronary artery disease in the family,  
cigarette smoking, systemic hypertension,  LDL cholesterol, and  diabetes 
mellitus. Apart from that, various novel risk factors 
16 
have been identified like  
endothelial dysfunction, lipoprotein (a), homocysteine, and C-reactive protein. 
Delineation of  risk factors 
16
in coronary artery disease has a very significant 
role  in its management  . 
 
                               In  acute coronary syndrome, platelets have a major role in  
 
 thrombus formation on the ruptured atherosclerotic plaque and consequent 
progression to myocardial  infarction
12
 .  The role of platelets in acute 
myocardial infarction and developments of complications have been well 
established . Therefore platelet inhibitors like, acetyl salicylic acid, 
thienopyridine, and glycoprotein IIb/IIIa inhibitors, are used in the treatment of 
2 
 
acute coronary syndromes .The circulating platelet, at a time, in a person differ 
in size, density, and activity 
4
 . Alterations of these parameters may be 
associated with pulling the trigger of acute coronary syndrome and further 
complications 
1
. The adhesive capability of large platelets are more and hence 
they tend to aggregate more than smaller ones 
1
. Increase in size of platelets as 
implicated by platelet volume may contribute to increased tendency of thrombus 
formation on atherosclerotic plaque in acute coronary syndrome 
2, 4
.  This study, 
aims to investigate the association between mean platelet volume and acute 
coronary syndrome and its use as a diagnostic tool , in comparison with control 
group. 
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REVIEW OF LITERATURE 
 
     The role of platelets in acute myocardial infarction has been appreciated for  
 
several decades. Yet the last 5-10 years have seen a dramatic increase in the  
 
understanding, development, clinical evaluation and therapeutic application of  
 
platelet inhibitor therapy.  
                             
                    In 1841   Addison  described  platelets  as “extremely  
 
minute granules” in clotting blood  and  the name  “platelets” was assigned to  
 
it  by Bizzozero.  Their adhesive qualities as „increased stickiness when a 
 
 vascular wall is damaged‟ were also explained by him .  Osler and by Hayem in  
 
the late  nineteenth century  identified platelets  in microscopic examination of  
 
blood smear. 
 
 
 
PLATELET STRUCTURAL AND FUNCTIONAL ANATOMY  
 
Light Microscopy 
 
     On Wright-Giemsa stained blood smears, platelets appear as small anucleate, 
 
 ovoid or round cells, with a pale grayish blue cytoplasm that contains  
 
homogenously distributed purple-red granules
 50
. 
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Platelet light microscopy 
 
Dimensions 
 
Platelets vary in number, size, density, age, and apparent physiologic 
effectiveness. The normal platelet count varies between 150 to 400,000 per µl, 
and normal platelet size (mean platelet volume) varies between 7.5 and 10.5 fl
50
. 
      
Electron Microscopy and Subcellular Organelles 
 
By scanning electron microscopy, circulating resting blood platelets appear as  
 
flat discs with smooth contours, rare spiny  filopodia , and random openings of a  
 
channel system, the surface-connected  canalicular system (SCCS), which  
 
invaginates  the platelet and is the conduit by which granule contents 
 
 exocytose after stimulation 
51
. Although the platelet is anucleate, 
 
 transmission electron microscopy reveals a complex surface and a cytoplasm 
 
 packed with a number of different subplatelet structures and organelles that are  
 
5 
 
essential to the maintenance of normal hemostasis 
  
Glycocalyx 
 
     Structure: A glycocalyx, 15 to 20 nm thick, is visualized by  
 
transmission  electron microscopy and contains glycoproteins, glycolipids, 
 
 mucopolysaccharides, and adsorbed plasma proteins. 
 
     Function: The glycocalyx has a net negative surface charge due to sialic 
 acid residues on the proteins and lipids; the charge is thought to minimize  
attachment of circulating platelets to each other . This structure is 
rich in carbohydrate moieties of membrane-associated glycoproteins, which  
serve as receptors to mediate transfer of signals by stimulatory agents. The  
glycocalyx interacts with platelet activators to facilitate platelet adhesion and  
aggregation. 
 
Plasma Membrane 
 
     Structure: The platelet plasma membrane is a typical trilaminar  
 
membrane (20 nm thick)with glycoproteins, glycolipids, and cholesterol  
 
embedded in a phospholipid bilayer. 
 
     Function: The plasma membrane contains sodium and calcium ATPase  
 
pumps, which are important for maintaining ionic homeostasis. It has a  
specialized role in providing a surface for the acceleration of blood coagulation,  
in that a specific platelet coagulant protein, platelet factor 3, resides in this  
6 
 
lipoprotein-rich unit membrane. 
 
Surface-connected Canalicular System  
 
     Structure: The surface-connected canaclicular system 52, also called the 
open canalicular system, weaves throughout the cell cytoplasm in a tortuous  
fashion. 
 
     Function: The functions of the surface- connected canalicular system52  
are to provide  route of entry  and  egress for molecules, an internal reservoir of  
membrane to facilitate platelet spreading and filopodia formation after adhesion 
 and a storage reservoir for membrane glycoproteins that increase on the platelet  
surface after activation. 
 
Dense Tubular system 
 
     Structure: The dense tubular system is a closed-channel  system consisting 
of narrow, membrane limited tubules approximately 40-60 nm in diameter. It 
contains amorphous, moderately  electron-dense material  
resembling cytoplasm within its lumina.  It is, infact, residual smooth  
endoplasmic reticulum from the megakaryocytes. 
 
     Function: This channel system is involved in the regulation of  
intracellular calcium transport because it has been reported to selectively bind,  
7 
 
sequester, and release divalent cations after activation. The dense tubular system  
is also the  site  of prostaglandin synthesis in platelets
53
. 
 
Cytoskeleton 
 
     General structure: The platelet cytoskeleton contains 30 to 50% of  
total platelet protein and is made up of three major structural components: an  
actin microfilament network present throughout the cytoplasm, a microtubule  
coil localized at the platelet periphery and a membrane skeleton comprising a  
network of short actin filaments that underlies the inner surface of the plasma  
membrane. Although they are distinct structures, interconnections between  
these elements are  present. 
 
     Structure and Function of Specific Cytoskeletal Elements 
 
            Actin Microfilaments: Twenty to thirty percent of total platelet protein 
is made of actin (Pollard, 1990). Actin exists in two forms, G-actin (actin 
monomers) and F-actin (polymerized actin). In the unstimulated platelet, 30 to  
40% of actin is polymerized into filaments; the balance of actin monomers are  
prevented from polymerizing by proteins such as profiling or thymosin B4 that  
sequester monomeric actin, or by proteins that cap filaments in the intact cell, 
such  as gelsolin
54
. 
 
Upon platelet activation, the proportion of filamentous actin rapidly increases to  
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60-70%. Actin monomers polymerize onto filaments at platelet peripheries and  
 
bundles of new filaments form to fill developing  filopodia. 
 
            Microtubules: A circumferential microtubule band that supports the 
discoid form of the platelet is made up of two non identical subunit proteins 
(Alpha and Beta tubulin) associated with microtubule associated proteins 
(MAPs). The 25 nm diameter microtubule coil lies adjacent to, but does not 
touch the plasma membrane. Microtubules are present primarily in their 
polymerized form in unstimulated platelets. Platelet activation results in 
microtubule disassembly, then reassembly; such alterations in the marginal 
microtubule bundle result in platelet shape changes
53
. 
 
            Membrane Skeleton: The short actin filaments of the membrane 
skeleton, which underlie the inner surface of the plasma membrane, together 
with the microtubule coil, are thought to help stabilize the platelet discoid 
shape. Two major platelet membrane glycoproteins, GP IIb-IIIa and  GP Ib-IX 
are  associated with the membrane skeleton. 
Granules 
 
     Platelets contain four distinct populations of granules: alpha granules, dense  
bodies, lysosomes, and microperoxisomes
50
. After platelet stimulation by 
agonists, granules fuse with channels of the surface-connected canalicular 
system and extrude their contents (White, 1974). Internal contraction is required 
for this extrusion and ultimate discharge into the surrounding medium. 
9 
 
 
            α- Granules : 
 
     Structure: α Granules are the predominant granule type  with a 
cross-sectional diameter of approximately 300 nm. The α granule has been  
subdivided morphologically into three distinct zones by electron microscopy: an  
electron-dense nucleoid that occupies the bulk of the granule, a peripheral zone 
of  lower electron density that lies adjacent to the granule membrane and 1 to 6 
tubular structures that reside in the electron lucent peripheral zone.  
 
    Content:β -thromboglobulin and platelet factor 4 have been localized to the 
dense nucleoid. Von Willebrand factor is present in the tubular structures of the 
granule peripheral zone. Thrombospondin, and fibrinogen are present in the 
 granular matrix. Other proteins present in α granules include albumin,  
immunoglobulin G (IgG), fibronectin, platelet derived growth factor, GP IIb-
IIIa, Beta amyloid protein precursor, factor V, multimerin, a factor V/Va 
binding protein, transforming growth factor β1 and a plasminogen activator 
similar to tissue plasminogen activator. 
Proteins present on the α-granule membrane include P-selectin, GP IIb-IIIa,  
granule membrane protein-33 (GMP-33), CD9, platelet-endothelial cell 
adhesion molecule 1 (PECAM-1) and osteonectin. 
 
 
10 
 
            Dense Bodies: 
 
     Structure: Ultrastructurally, dense granules have a bull‟s eye appearance. 
They are the most electron-dense organelles in platelets. With an approximate 
diameter of 250 nm, these granules contain a large reservoir of ADP, a critical 
agonist for platelet activation that amplifies the effect of other stimuli  
      
Content: The principle constituents of dense granules are a non metabolic 
 pool of adenosine nucleotides (adenosine triphosphate and diphosphate, ATP 
andADP), PPi, calcium and magnesium and serotonin (5-hydrotryptamine). In  
addition, dense bodies contain guanosine triphosphate and diphosphate (GTP 
and GDP). The dense granule membrane contains P-selectin and granulophysin.   
 
            Lysosomes: 
 
     Structure:  Lysosomes are small, acidified vesicles, approximately 200 nm 
in diameter, that are identifiable only with specific cytochemical stains for acid 
phosphatase and aryl sulfatase  or through immunocytochemistry for 
cathepsin D and lysosome-associated membrane proteins 
 
     Content: Lysosomes are the only platelet granules that contain acid 
hydrolases. Platelet lysosomes contain a large variety of enzymes, including 
11 
 
 β hexosaminidase and β glycerophosphatase. Lysosomal membrane 
glycoprotein (LIMP-CD63) and  lysosomal associated membrane proteins 1 and 
2 (LAMP-1 and LAMP-2) become expressed on the plasma membrane after 
activation. 
 
            Microperoxisomes: 
 
     Structure: Microperoxisomes are small (90nm) granules that are relatively 
few in number in platelets and can be demonstrated only cytochemically. 
 
     Content: They are reactive with alkaline diaminobenzidine medium. The 
 enzyme responsible for the cytochemical peroxidase activity in 
microperoxisomes is catalase. 
 
Coated Vesicles: 
 
     Structure: Coated vesicles are 70 to 90 nm organelles 
 
     Content: The polyhedral coat on the surface of these vesicles is  
 
composed of clathrin.  Plasma components are transported to platelet  
 
granules by coated pits and vesicles. 
 
Mitochondria 
 
     Structure: Mitochondria in platelet are similar, with the exception of  
 
smaller size to those in other cell types. There are approximately seven per  
 
12 
 
human  platelet. 
 
     Content: Mitochondria are the site of activity for all components of the 
 
 respiratory chain and for almost all enzymes in the citric acid cycle. 
 
Glycogen 
 
     Platelets contain small particles of glycogen or masses of closely associated  
 
glycogen particles; these play an essential role in platelet metabolism. 
 
    
PLATELET PHYSIOLOGY 
 
A GLOBAL VIEW:  The point of this “global view” is to emphasize a limited  
number of major current features of platelet physiology. To begin, it is fair to 
say  that the platelet has come a long way from its past as an “inert particle” or 
possible  artifact 
55
 to its present recognition as a remarkable fragment of 
megakaryocyte cytoplasm, capable of intense, focused activity that produces a 
tenacious mass at a site of vessel damage or disease . The clinical  
relevance of platelets is well illustrated by the widespread use of platelet gpIIb-
IIIa antagonists (e.g., abciximab, eptifibatide) during angioplasty 
56
 and by  the 
general acceptance of aspirin as an antiplatelet agent to prevent heart attack and  
stroke 
57,58 
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Electron microscopic view of platelets 
 
 
 
 
(Diagram of a human platelet displaying its components) 
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Platelet Lipids and Proteins 
 
Membrane Lipids 
 
     Phospholipids constitute 80% of the total platelet lipid, although smaller 
 amounts of neutral lipids and glycolipids are also present. The five major 
 phospholipids identified in human platelets are phosphatidylcholine,  
phosphatidylethanolamine, sphingomyelin, phosphatidylserine and  
phosphatidylinositol. Almost all platelet fatty acids are esterified in 
phospholipids, leaving only trace amounts of free fatty acids. Arachidonic acid, 
the precursor of  prostaglandins and thromboxanes, is enriched in these 
phospholipids and the metabolism of arachidonic acid is critical for normal 
platelet function (Marcus, 1976). Neutral lipids make up approximately 28% of 
total platelet lipids, the predominant  neutral lipid being cholesterol. 
 
Membrane Glycoproteins 
 
     Platelet membrane glycoproteins mediate a wide number of adhesive cellular 
 
 interactions. These glycoproteins function as receptors that can receive signals 
 
 from outside the platelet, facilitating cell-cell interactions; binding of specific 
  
ligands to these receptors result in distinct platelet responses to the external  
 
environment. 
 
            Glycoprotein IIb-IIIa: Glycoprotein IIb-IIIa is the principal  
 
receptor on the platelet plasma membrane (Philips et al, 1988). It  belongs to  
15 
 
 
the integrin family of proteins. A Ca
2+  
dependent conformational change in 
  
GP IIb-IIIa after platelet agonist induced stimulation facilitates strong binding 
to  fibrinogen and VWF resulting  in  platelet aggregation. 
 
            Glycoprotein Ib-IX: Platelets interacts with VWF with the help of  
glycoprotein  Ib receptors. GP Ib also functions as a binding site for thrombin.  
GP Ib is present on platelet surfaces in a 1:1 ratio with GP IX. 
 
            Other membrane Glycoproteins: Membrane glycoproteins GPIa-IIa, 
 
 GPIc-IIa, helps in adhesion of  platelet  to collagen,   laminin  and  
 
fibronectin . GP V forms a non covalent complex with GP Ib-IX in the platelet 
 
 membrane. PECAM-1 binds to heparin like molecules. GP IV is a receptor for 
 
 thrombospondin. GP IV is also reported to bind collagen. 
 
Other Platelet Proteins 
 
     Other proteins present in the platelet are platelet factor 4,  
β thromboglobulin, thrombospondin, platelet derived growth factor, fibronectin.  
 
            Platelet Factor 4 (PF4): The anticoagulant activity  of  heparin is 
neutralized by binding  with  PF4. Other activities like,  potentiation of platelet  
aggregation also mediated by PF4.  Heparin administration can mobilize this 
endothelial-bound pool of  PF4 into the circulation . PF4–heparin complexes 
and  PF4 –heparin-like molecule complexes on endothelial cells have been 
16 
 
implicated as the target antigens in heparin-induced thrombocytopenia with 
thrombosis  PF4 also binds to hepatocytes, which take up and catabolize  PF4. 
PF4  is a weak neutrophil and fibroblast attractant. It inhibits angiogenesis, 
perhaps through inhibition of endothelial cell proliferation. Other functions  of  
PF4 including histamine release from basophils, inhibition of tumor growth
 
 and 
megakaryocyte  maturation, reversal of immunosuppression, enhancement of 
fibroblast attachment  to substrata, potentiation of platelet aggregation 
 
 
 
 
 
Diagram demonstrating the platelet adhesion and activation.  
 
Activated platelets release  dense platelet granules containing adenosine  
5′diphosphate (ADP) and thromboxane A2 (TxA2) , which results in 
aggregation and activation of other platelets and thereby amplifying the effect. 
17 
 
Drugs such as clopidogrel (C) and ticlopidine (T), block ADP-receptor 
mediated platelet activation. Aspirin causes inhibition of cyclooxygenase 
(COX), thereby  decreasing the synthesis of prostaglandins  G2 and H2, which 
lead to reductions in production of thromboxane A2 (TxA2) by thromboxane 
synthase (TxS). 
 
PLATELET BIOCHEMISTRY 
 
     The platelet has minimal ability to synthesize protein because it contains 
only low levels of RNA and lacks a nucleus. In terms of dry weight, the platelet 
is  composed of approximately 60% protein, 15% lipid and 8% carbohydrate. 
Platelet  minerals include magnesium, calcium, potassium and zinc. Platelets 
contain substantial amounts of vitamin B12, folic acid and ascorbic acid. 
 
Platelet Energy Metabolism 
 
     There are several similarities between the energy metabolism of the platelet 
 and that of skeletal muscle. Both involve active glycolysis and the synthesis 
and  use of large amounts of glycogen and in both, the major mediator of 
intracellular  energy use is an actinomysin-like adenosine triphosphate. The 
platelet, like muscle  is metabolically adapted to expand large amounts of 
energy rapidly during  aggregation, the release reaction and clot retraction. 
The major energy source for the platelet is glucose, which is rapidly taken up 
from  the plasma. Platelet energy is derived from the metabolism of glucose and 
18 
 
to a lesser extent from the metabolism of fatty acids. Energy is provided in 
approximately equal  amounts by glycolysis and the citric acid cycle. Platelet 
energy reserve is provided  by the metabolic pool of platelet nucleotides that is 
in a state of continuous  turnover. 
 
Nucleotide Metabolism 
 
     Adenine nucleotides constitute 90% of free platelet nucleotides and are  
partitioned into at least two different pools, which undergo minimal 
interchange. The metabolic or cytoplasmic pool makes up 40% of total adenine 
nucleotides; it is  used for the maintenance of various energy consuming cell 
functions and is retained during platelet release. 
The storage pool, which is present in the dense bodies, contains approximately  
two-thirds of the total platelet nucleotides, mainly in the form of ADP and ATP. 
It  is metabolically inactive, does not rapidly incorporate exogenous adenine or  
phosphate, and equilibrates slowly with the metabolic pool.  Nucleotides in this 
 pool are extruded from the platelet during the release reaction and cannot be 
 replenished after release. ATP hydrolysis is required for conversion of G-actin 
to F-actin. The ATP that is broken down to provide energy for the release 
reaction is  not rephosphorylated, but rather is irreversibly degraded to 
hypoxanthine which diffuses out of the cell. Platelets also contain guanine 
nucleotides and uracil and cytosine pyrimidines. 
 
19 
 
 
 
Arachidonate Metabolism 
 
     Arachidonic acid is released from platelet membrane phospholipids after  
 
stimulation by numerous agonists through the enzyme action of phospholipase 
A2 or the combination of phospholipase C and diglyceride lipase.  After release, 
arachidonic acid can be acted on by either lipoxygenase, which results in the  
production of peroxy and hydroxyl fatty acids, or by cyclooxygenase, which 
 ultimately results in production of  thromboxanes and prostaglandins. 
 
Platelet “Coagulation” Factors 
 
     Numerous platelet proteins interact with plasma coagulation proteins 
although  the mechanism by which platelet membrane component becomes 
reorganized and capable of functioning as a catalytic surface for plasma proteins 
are not known. 
 
Several plasma coagulation factors are associated with platelets, including  
 
von Willebrand factor, coagulation inhibitors, and factor XIII. 
 
Various substances associated with or derived from the platelet have been 
 
 designated platelet factors 1 to 10 and denoted by Arabic numerals. The most 
 
 important of these are PF4 and PF3. 
 
            Platelet Factor 3 
 
     PF3 is required in at least two steps in the process of blood coagulation, 
20 
 
 
 namely the interaction between factors IXa and VIIIa, which results in the  
 
activation of factor X, as well as the interaction between factor Xa and factor Va  
 
which leads to the formation of prothrombinase. These coagulation reactions are  
 
greatly accelerated on the platelet surface. 
 
 
 
PLATELET COUNT 
 
     The normal platelet count varies between   1,50,000-3,50,000/mm3 
 
 
 
PLATELET VOLUME 
  
The  normal mean platelet volume varies between  6 – 11 fl ( wintrobes 12th ed). 
 
 
          
ORIGIN OF PLATELETS FROM MEGAKARYOCYTES 
 
     The megakaryocyte is a large hematopoietic cell, the cytoplasm of which  
 
fragments to form circulating blood platelets. The histogenesis of platelets from 
 
 megakaryocytes was first described by James Wright in 1910.     The  
 
megakaryocytes are sessile polyploid cells which in turn descend from diploid  
 
pluripotent hematopoietic stem cells of marrow. The megakaryocytes are  
 
imprisoned within the sub endothelial layer of marrow sinuses by their very 
girth and volume (average 5000 femto litres, Zhang YJ, 1991). In these marrow 
niches,  mononuclear progenitors undergo diploid doublings by the unique 
process of  endomitosis. Subsequently the polyploid megakaryocytes 
21 
 
accumulate a bulky  compartmentalized cytoplasmic mass with large volumes 
that at end stage maturation disintegrates abruptly to yield between 1000 and 
8000 platelets having  a volume of 7-9 femto litres each (Martin et al, 1982; 
Stenberg and Levin, 1989;Corash, 1989). Megakaryocytes are suicidal 
microorgans whose mission is to  proliferate and then fragment their cytoplasm 
on demand to maintain blood platelets at relatively steady levels of about 
1,50,000-3,50,000/mm
3. 
 
Maintenance  of  platelet counts within this range represents
 
a surplus of over 10  
times that is  necessary to ensure routine haemostasis but provides a 
precautionary reserve for times of excess platelet loss or consumption. 
 
PLATELET LIFE SPAN, TURN OVER & REMOVAL 
  
     Platelet life span, based on the time required to clear labelled platelets from  
circulation, has been estimated to be 8-12 days in humans. The sites for platelet  
removal appear to be spleen, the liver and bone marrow.  Degranulation and 
loss of density and platelet constituents has not been shown to decrease platelet 
life span indicating that the number of  haemostatic interactions may not be a 
key component. 
 
 
PLATELET ADHESION, ACTIVATION & AGGREGATION 
 
     The anti thrombotic properties of intact vascular endothelium include potent 
22 
 
 
 platelet inhibitors. These inhibitors include PGI2, NO and CO which are labile 
 
 molecules that are released by endothelial cells and act locally as autocoids and 
 
 ADPase, an ectonucleotidase of endothelial membranes that breaks down  
 
platelet  activating ADP. 
 
 
 
 
 
Adhesion 
 
     On vascular intimal injury, the antiplatelet properties of endothelium are  
 
diminished locally, while previously cryptic, thrombogenic  subendothelial  
 
substances eg.collagen become exposed to flowing blood. Circulating platelets 
 recognize sites of vascular disruption and undergo the process of adhesion to 
the  site of injury.   von willebrand factor mediates platelet adhesion, which is  
23 
 
present in the extracellular matrix of sub endothelial vessel wall. The receptor 
of von willebrand factor on the platelet surface is localized in membrane glyco- 
 protein (Gp) Ib, part of the platelet membrane Gp Ib/IX-V complex.  The  
progression of  platelet adhesion is also assisted by direct binding to 
subendothelial collagen via specific collagen receptors in platelet membranes 
 
 
 
Activation 
 
     Adherent platelets then become activated. The platelet activation process  
results from the combined actions of several agonists that bind to their 
respective membrane receptors on adherent platelets and transmit platelet 
activating  intracellular signals. Activated platelets then undergo release 
reaction during which  they secrete pre-packaged constituents of their  
cytoplasmic granules. The  constituents released from dense granules are ADP, 
ATP serotonin. The constituents released from alpha granules are soluble 
adhesive  proteins (fibrinogen, von willebrand factor, thrombospondin, 
fibronectin), growth  factors (PDGF, TGF α, TGF β), procoagulants (platelet 
factor 4, Factor V). Simultaneously, activated platelets synthesize de novo and 
release the potent platelet activator and vasoconstrictor thromboxane A2 
(TXA2). 
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Aggregation 
 
     The activated platelets release certain products, including secreted granule  
constituents and TXA2  mediate aggregation.  During platelet aggregation 
 (platelet-platelet interaction), additional platelets are recruited from circulation 
to the site of vascular injury.  Ultimately an occlusive thrombus is formed. 
At lower shear levels (eg. In venous circulation), the molecular glue that  
mediates aggregation is fibrinogen, which can be derived either from plasma or  
from the alpha granule releasate of activated platelets. At higher shear level, 
 (eg. In arteries) von willebrand factor can substitute for fibrinogen as the ligand 
of  aggregation. Fibrinogen or von willebrand factor binds to the specific 
platelet  membrane receptor that are located in the Gp IIb/IIIa integrin complex 
and  mediates aggregation and finally the platelet plug is formed. The platelet 
plug is  anchored and stabilized by the fibrin mesh that develops simultaneously 
as the  product of the coagulation cascade. 
 
PLATELET VOLUME & CARDIOVASULAR DISEASE 
 
    The platelets have a major role in the biological events immediately 
forerunning  the acute coronary events. The changes in platelet structure has  a 
significant role  in  begetting  a thrombus . The thrombus enrooting on a  
coronary  atherosclerotic plaque is the ultimate cause for all acute myocardial 
infarctions.  In  unstable angina also thrombus is the major triggering factor
11
 . 
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Platelet activation  therefore plays a significant role in all acute coronary events. 
As the initial step in  the pathogenesis of acute  myocardial infarction is plaque 
erosion or rupture  followed by platelet adhesion, activation and aggregation 
followed by thrombus  formation, platelets with more activity will predispose to 
the  occurrence of myocardial infarction.  
                  
                 Martin JF et al.in 1983 showed that mean platelet volume which  
 
represents platelet size relate mutually to their reactivity . 
 
Jakubowski JA, Giles et al in 1992 described  circulating  platelets as having  
 
multifarious  size, density, and reactivity. Their study showed that mean platelet  
 
volume is positively associated with indicators of platelet activity including  
 
expression  of   glycoprotein Ib and glycoprotein IIb/IIIa receptors . 
 
 
 Endler G, Bath P et al in 2004 proved in their study ,that  patients with 
myocardial infarction  and unstable angina are characterized with higher values 
of mean  platelet volume  as compared to those with stable angina or noncardiac 
chest pain,  and recognized mean platelet volume  as an independent risk factor 
for myocardial infarction and stroke . 
                         
 
 
Keskin O and Ulusoy RE et al in 2004 showed a poor clinical outcome among  
survivors of myocardial infarction  associated with elevated MPV. 
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 Corash ey al in 2000 in their study using in vitro aggregometry proved that 
large  platelets are metabolically and enzymatically more active25 than small  
platelets, and  their thrombotic potential is much higher than the smaller ones 
 which was explained by  Karpatkin et al in 1972. 
                               
                               Mathur et al and Pathansali et al in 2001 showed that large  
 
platelets  expressed higher levels of procoagulatory surface proteins such as  
 
P-selectin  and glycoprotein IIIa . 
                               Janusz  Kochman,et al in 2005  studied the significance of   
Mean platelet Volume on admission and disclosed that it predicts impaired  
reperfusion and long term mortality in acute myocardial infarction treated with  
primary percutaneous coronary intervention 
 
Large platelets are denser and aggregate more rapidly than their smaller  
 
counterparts and expressed more receptors per unit area (Pizuli et al 2000) 
 
When Cox DA, Stone GW et al 2006  compared MPV for both STEMI and  
 
NSTEMI groups, they found higher MPV values for STEMI compared to 
healthy  controls, which was consistent with larger and reactive platelets 
inciting an  increased prothrombotic state leading to consumption of larger and 
reactive platelets  
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Platelet volume and prognosis following acute myocardial infarction 
 
     Hendra et al(1988) observed that all patients with severe cardiac failure had  
 
larger platelet volumes than patients with mild or no failure. Osuna et al (1998)  
 
stated that increase in mean platelet volume on admission was an independent 
risk factor for cardiac failure. 
 
Increased MPV was found to be an independent risk factor for recurrent  
 
myocardial infarction by Martin et al (1982). 
 
Yilmaz et al (2004) observed that in patients with dilated cardiomyopathy and 
in sinus rhythm, an increased MPV was associated with an increased incidence 
of left ventricular thrombus. 
 
In contrast to the above observations, Cameron et al (1983) noted that the 
increase  in MPV did not appear to provide any prognostic information after 
myocardial  infarction. The value in patients who dies was no different from 
that of the  survivors. The MPV did not correlate with the more established 
factors  determining prognosis after myocardial infarction such as size of the 
infarct. 
 
AGE, SEX AND MPV 
 
     Funiak et al (1994) observed increased MPV in patients of advanced age. In  
 
contrast Bancroft et al (2000) observed decreased MPV with advanced age. He  
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observed no difference between genders. 
 
 
 
 
 
MPV AND SMOKING 
 
     Smokers were found to have an increased MPV (Tschope et al, 1989; Kario 
et  al, 1992). 
 
 
MPV AND OTHER DISEASES 
 
     An increase in MPV was observed in diabetics compared with non diabetics 
by  Sharpe et al (1993). 
 
     Although Osuna et al (1998) observed a higher MPV in those with systemic  
 
    hypertension, Bath et al (1996) observed no such effect. 
  
    Ford et al (1998) observed that patients with hyperthyroidism had increased   
 
   MPV. 
 
       Bansal et al (2002) stated that MPV was increased in patients with  chronic 
obstructive pulmonary disease and this could possibly contribute to an increased  
   incidence of pulmonary embolism in these patients. 
 
     In chronic liver disease, MPV and platelet count are decreased (Jorgensen et    
al, 1984). 
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  AIMS AND OBJECTIVES    
 
1) To investigate the association  between mean platelet volume and acute 
coronary syndrome in patients with diagnosis of acute coronary disease, in 
comparison with control group 
2) To find out the role of mean platelet volume in short term outcome after 
myocardial infarction 
3) To identify whether  any association exists between mean platelet volume 
and  other selected  factors like age ,sex,  smoking, systemic hypertension and 
diabetes mellitus 
4) To check the  sensitivity and specificity of  mean platelet volume when 
compared to Troponin-T 
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                                MATERIALS AND METHODS 
 
Setting                               :   Department of  Internal Medicine and Intensive  
                                             coronary care unit , Thanjavur medical college,                
                                            Thanjavur    
Collaborative  department:  Department of cardiology, Thanjavur   medical 
college ,Thanjavur 
Design of study                :  Comparative cross sectional study 
Period of study                 :    April 2012 to November 2012 
Sample size                       : Total 111, study group 86, control 25 
Inclusion criteria               : Patients  who had  history suggestive of  acute 
coronary syndrome, whose  ECG showed typical ST segment deviation with 
other  laboratory  evidence 
Exclusion criteria              : 
1) Not having typical ECG changes 
2) Presence of  septicemia 
3)  Known cases of any haematological disorders 
    4) Presence of blood loss 
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    5)Presence of hyperthyroidism  
    6) Presence of chronic heart disease 
   7) Presence of chronic renal failure 
   8) Past history of cerebrovascular accident 
   9) Known case of any malignancy 
10) Past history of coronary artery disease 
CONTROLS 
Age and sex matched subjects who had  atypical chestpain, without ECG or 
laboratory evidence of  coronary artery  disease or history of previous 
coronary  artery disease were kept as controls 
CONSENT 
Informed consent was obtained from all those who participated in the study 
or their relatives 
MATERIALS 
Thus a total of  45 MI patients & 41 Unstable angina patients who satisfied 
the inclusion and exclusion criteria stated above were taken up for 
subsequent study. 25 age and sex matched subjects were kept as control. 
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DEFINITIONS USED FOR THE STUDY 
1) Acute myocardial infarction (AMI) :  
 
The diagnosis of AMI was established by three criteria accepted by 
WHO: 
1. Ischaemic type of  chest pain typical of AMI 
2. Changes in serial ECG tracings typical of AMI  
3. positive cardiac biomarkers 
       2) Unstable angina: 
          The diagnosis of unstable angina pectoris was established by the 
presence   of   unstable  chest pain and  typical ECG findings in the absence 
of  elevated cardiac bio markers 
3) smoking: 
                   A subject was considered to be a smoker if he or she gives history          
               of   smoking  within the past 20 years , persons who  had quit smoking        
                completely   before  20 years were not considered as smokers  
4) Systemic hypertension: 
                         A subject was considered to have systemic hypertension  if  
he  or she was already diagnosed to have systemic hypertension and was on 
anti- hypertensive  medications or if the systolic blood pressure during the 
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hospital  stay   was to be more than or equal to 140 mm hg and for diastolic  
B.P was more than or equal to 90 mm hg 
     5) Diabetes mellitus: 
 A subject was considered to have diabetes if  he/she was 
already diagnosed to have diabetes mellitus or during the hospital stay, was  
found to have a 
        - fasting plasma glucose ≥ 126 mg/dl 
        -2 hr post prandial  plasma glucose ≥ 200mg /dl 
       - symtoms of diabetes mellitus plus random blood sugar  ≥200mg/dl 
6) Left ventricular dysfunction: 
 
      Left ventricular dysfunction was  divided to mild, moderate and severe  
according to ejection fraction on ECHO < 29% severe , 30-39% moderate ,  
40 -49% per mild 
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SHORT TERM OUTCOME 
 
     Outcome at the end of 7 days after MI was considered with respect to 
left  ventricular dysfunction ,   occurrence of arrhythmia , occurrence of 
death. 
 
METHODS 
   Selected socio-demographic , clinical and laboratory value was collected 
 from patients and controls and recorded in proforma (enclosed in 
annexure) 
1) Socio demographic data composed of 
 
.age 
 
.sex 
 
. smoking 
 
.diabetes and hypertension 
 
       2)clinical data  
 
       3)laboratory data  
         .Random blood sugar 
         .Total cholesterol 
         .ECG 
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         .echocardiogram, troponin T 
         .platelet count 
         .mean platelet volume 
ECG    - 12 lead multi channel ECG was taken in all patients 
ECHO-                         
 Trans thoracic echo was done using  NOS TRIVITROX  in all the cases . 
 2- D ECHO, M- MODE ECHO was done to analysis the regional wall motion 
abnormality  presence of clot & also to assess the left ventricular function.  
Colour  Doppler  was done to evaluate  the  presence of  valvular  regurgitation 
and  also to assess the diastolic dysfunction. 
     For the above mentioned haematological parameters ,  2ml of blood was  
withdrawn by vene puncture from the patient within 24 hrs of admission to the 
 hospital. The puncture site was properly cleansed and blood withdrawn and  
collected in EDTA containing disposable tubes .The sample was transfused  
immediately to a quality controlled centre where the sample was analyzed for 
 platelet volume. The instrument used for analysis was LOBAS MICROS  OT 
18 automated hematological analyzer made by ROCHE. 
               The instrument was started .    After start up , a pipette appeared from 
the  instrument . blood sample was fed to the instrument by the principal 
worker. The  principle drew the necessary amount of blood and withdrew on its 
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own after taking  the necessary amount of blood.   A waiting time of 180 
seconds appeared on the  instrument, then at the end of 180 seconds a printout 
with the platelet count and  mean platelet volume was ejected from the printer 
connected to the instrument. 
 The instrument was repeatedly standardized for quality control. 
CONFLICT OF INTEREST 
                         There  was no conflict of interest 
FINANCIAL SUPPORT  
Nil 
 
 
STATISTICAL ANALYSIS: 
     Data  were entered in Microsoft excel spread sheet and analyzed utilizing the  
software STATA version 12 and SPSS version 17.  ROC curve was calculated  
using MEDCALC.  
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OBSERVATIONS AND RESULTS 
Total   number of subjects included in the study was 111. Among the 111 
subjects 45 had myocardial infarction (MI), 41 unstable angina and 25 controls . 
Their baseline characters are provided below. 
Age and Sex distribution 
Age:  
The age of MI cases ranged from 28 to 78 years with mean age 
55.18±12.881,  unstable angina ranged from 30 to 80 years with mean age 
53.73±13.504  and control ranged from 32 to 68 years with mean age 
49.20±10.516 . The distribution of  cases  and controls with respect to age is 
given in Table -1 given below: 
 
Table – 1 ( Age Distribution in the 3 Groups) 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
MI 45 55.18 12.881 1.920 51.31 59.05 
Unstable 
Angina 
41 53.73 13.504 2.109 49.47 57.99 
Control 25 49.20 10.516 2.103 44.86 53.54 
Total 111 53.30 12.733 1.209 50.90 55.69 
 
N- number, Std- standard. 
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One way ANOVA test was done and the „p‟ value was 0.164 which proved that  
there was no significant difference in the distribution of age , between the 
groups 
Sex composition : 
Among the 86 cases studied in MI and Unstable angina groups, there were 33 
malesand 12 females in MI group, 29 males and 12 females in the Unstable 
angina group. Among the control group, there were 15 males and 10 females. 
The sex composition is given below in Table – 2. 
 
Table – 2 ( Sex Composition in the Study groups) 
 Cases  
Control MI Unstable 
angina 
SEX 
Male 33 29 15 
Female 12 12 10 
 
Chi- square test was done and the „p‟ value was found to be 0.126(>.05). Thus 
there was no significant difference in the sex distribution among the groups 
Comparison of Platelet Volume   in Study Groups 
 The Mean Platelet Volume in MI group is 9.84±0.67 and the values 
ranged from 8.6 to 11, in Unstable angina group mean MPV is 9.07±0.77 and 
the values ranged from 7.0 to 10.6 and in the Control group mean platelet 
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volume is 6.85±0.73 and the values ranged from 6.0 to 8.4. The mean platelet 
volume  values of the 3 groups is given below in Table – 3 . 
 
Table – 3 ( Mean Platelet Volume values in the 3 Study Groups)  
 
 N Mean Std. 
Deviation 
Std. Error 95% Confidence Interval for Mean 
Lower Bound Upper Bound 
MI 45 9.842222 .6767197 .1008794 9.638913 10.045531 
Unstable 
angina 
41 9.078049 .7734702 .1207957 8.833911 9.322186 
Control 25 6.852000 .7377443 .1475489 6.547474 7.156526 
Total 111 8.886486 1.3592435 .1290137 8.630812 9.142161 
 
 One way ANOVA was done to compare the mean MPV in the 3 groups 
and the „p‟ value was found to be significant. Hence the Mean MPV in the 3 
groups were significantly different. The Results of One way ANOVA are given 
in Table – 4         
Table-4 
                                 
 
 
 
 
 Sum of 
Squares 
Df Mean Square Sig.(‘p’) 
 Between 
Groups 
146.087 2 73.044 .000 
Within 
Groups 
57.142 108 .529 
 
Total 203.230 110   
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Following ANOVA , Post Hoc Tests with Tukey and Bonferroni Methods were 
used to detect the Significance when each group was compared to the rest. 
Following this, the results showed that every group is significantly different 
individually from the rest. The Post Hoc tests results in Tukey method are given 
below in Table – 5 and for Bonferroni method in Table – 6 . 
Table – 5 ( Post Hoc Tests – Tukey Method) 
 
 (I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig.(‘p’) 
Tukey 
HSD 
MI 
Unstable 
Angina 
.7641734* .1570430 .000 
Control 2.9902222* .1814430 .000 
Unstable 
Angina 
MI -.7641734* .1570430 .000 
Control 2.2260488* .1845770 .000 
Control 
MI -2.9902222* .1814430 .000 
Unstable 
Angina 
-2.2260488* .1845770 .000 
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Table – 6 ( Post Hoc Tests – Bonferroni Method ) 
 (I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig.(‘p’) 
Bonferroni 
MI 
Unstable 
Angina 
.7641734* .1570430 .000 
Control 2.9902222* .1814430 .000 
Unstable 
Angina 
MI -.7641734* .1570430 .000 
Control 2.2260488* .1845770 .000 
Control 
MI -2.9902222* .1814430 .000 
Unstable 
Angina 
-2.2260488* .1845770 .000 
 
Figure – 1 Plot of the Mean MPV in the 3 Groups 
 
Group 1 – MI 
Group 2 – Unstable Angina 
Group 3 - Control  
 
45 
 
 
 
Comparison ofPlatelet counts in the Study Groups: 
 The platelet counts in the study groups were compared. In the MI group 
the mean platelet count was 141800±63350 and the values ranged from 75000 
to 310000, in the Unstable angina group the mean was 138243±61436 and the 
values ranged from 80000 to 340000 and finally in the Control group the mean 
was 230800±56856 and the values ranged from 120000 to 340000. The mean 
and the standard deviation of the platelet count in the 3 groups in given below in 
Table – 7 . 
 
Table – 7 (Mean Platelet count in the 3 groups) 
 
 
 N Mean Std. 
Deviation 
Std. Error 95% Confidence Interval for Mean 
Lower Bound Upper Bound 
1 45 141800.00 63350.970 9443.805 122767.26 160832.74 
2 41 138243.90 61436.463 9594.764 118852.16 157635.64 
3 25 230800.00 56856.545 11371.309 207330.77 254269.23 
Total 111 160531.53 71652.294 6800.935 147053.68 174009.39 
 
One way ANOVA was done and the mean platelet counts significantly differed 
in the 3 groups with a significant „p‟ value . The results of the analysis are 
shown in Table – 8 . 
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Table- 8 
 Sum of Squares df Mean Square Sig.(‘p’) 
Between 
Groups 
159596878664.030 2 79798439332.015 .000 
Within Groups 405148760975.610 108 3751377416.441  
Total 564745639639.640 110   
 
 
 
Figure – 2 ( Plot of the Mean Platelet Count in the 3 Groups ) 
 
Group 1 – MI 
Group 2 – Unstable angina 
Group 3 – Control 
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ROC Analysis (Receiver operating characteristic) 
 This analysis is used to compare mean platelet volume with a Standard 
diagnostic test like Troponin T as in this study in order to assess the Sensitivity 
and Specificity of Mean platelet Volume in detecting MI. 
ROC curve 
 
 
Diagnostic Test MPV 
Standard Diagnostic 
Test 
Troponin T Test Strip. 
  
 
 
 
Sample size 111 
Positive group :  45 
Negative group :  66 
  
 
 On performing the analysis in Medcalc statistical software , a curve was 
obtained with the following features : 
 
Area under the ROC curve (AUC)  0.858 
Standard Error
a
 0.0342 
95% Confidence interval
b
 0.779 to 0.917 
z statistic 10.477 
Significance level P (Area=0.5) <0.0001 
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   Then various cut off points of MPV were chosen and their sensitivity and 
specificity were checked in the Curve 
  
Cut off value of MPV Sensitivity 95% CI Specificity 95% CI 
>=6 100.00 92.1 - 100.0 0.00 0.0 - 5.4 
>6 100.00 92.1 - 100.0 6.06 1.7 - 14.8 
>6.1 100.00 92.1 - 100.0 7.58 2.5 - 16.8 
>6.2 100.00 92.1 - 100.0 10.61 4.4 - 20.6 
>6.3 100.00 92.1 - 100.0 12.12 5.4 - 22.5 
>6.4 100.00 92.1 - 100.0 13.64 6.4 - 24.3 
>6.5 100.00 92.1 - 100.0 15.15 7.5 - 26.1 
>6.6 100.00 92.1 - 100.0 19.70 10.9 - 31.3 
>7 100.00 92.1 - 100.0 28.79 18.3 - 41.3 
>7.2 100.00 92.1 - 100.0 30.30 19.6 - 42.9 
>7.3 100.00 92.1 - 100.0 31.82 20.9 - 44.4 
>7.4 100.00 92.1 - 100.0 33.33 22.2 - 46.0 
>7.8 100.00 92.1 - 100.0 37.88 26.2 - 50.7 
>8 100.00 92.1 - 100.0 42.42 30.3 - 55.2 
>8.1 100.00 92.1 - 100.0 45.45 33.1 - 58.2 
>8.4 100.00 92.1 - 100.0 46.97 34.6 - 59.7 
>8.6 93.33 81.7 - 98.6 50.00 37.4 - 62.6 
>8.8 * 91.11 78.8 - 97.5 62.12 49.3 - 73.8 
>8.9 88.89 75.9 -96.3 62.12 49.3  -73.8 
>9 75.56 60.5 - 87.1 71.21 58.7 - 81.7 
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Cut off value of MPV Sensitivity 95% CI Specificity 95% CI 
>9.1 75.56 60.5 - 87.1 72.73 60.4 - 83.0 
>9.2 75.56 60.5 - 87.1 74.24 62.0 - 84.2 
>9.4 71.11 55.7 - 83.6 80.30 68.7 - 89.1 
>9.6 64.44 48.8 - 78.1 87.88 77.5 - 94.6 
>9.8 57.78 42.2 - 72.3 90.91 81.3 - 96.6 
>10 44.44 29.6 - 60.0 96.97 89.5 - 99.6 
>10.1 33.33 20.0 - 49.0 96.97 89.5 - 99.6 
>10.2 26.67 14.6 - 41.9 96.97 89.5 - 99.6 
>10.3 24.44 12.9 - 39.5 96.97 89.5 - 99.6 
>10.4 13.33 5.1 - 26.8 98.48 91.8 - 100.0 
>10.6 8.89 2.5 - 21.2 100.00 94.6 - 100.0 
>10.8 6.67 1.4 - 18.3 100.00 94.6 - 100.0 
>11 0.00 0.0 - 7.9 100.00 94.6 - 100.0 
  
 
 
In  ROC  curve analysis sensitivity is taken along the Y axis and 100-specificity 
is taken along the X axis. Curve is plotted as per the values of MPV compared 
to Trop- T which was the major diagnostic test. On plotting the curve , the top 
left portion of the curve is chosen to get the cut-off point with maximum 
sensitivity and specificity.So in my study the cut –off value of  8.8fl was at the 
top left point and it satisfied the criteria with the highest Youden Index. It has  
91.11% sensitivity and 62.12% specificity 
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ROC CURVE 
 
Possible determinants of MPV as analysed by Multiple Linear Regression 
 Mean Platelet Volume as a quantitative dependent variable was analysed 
with independent variables like age, Blood sugar and Blood Cholesterol values 
through Multiple linear regression.  The Regression Co-efficients of the 
Independent variables are given below in Table – 8 . 
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Table – 8 ( Regression Coefficients of the Independent Variables )  
 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig.(‘p’) 
B Std. Error Beta 
1 
(Constant) 3.151 1.130  2.789 .006 
CHOLESTEROL .020 .005 .355 3.972 .000 
SUGAR .006 .003 .183 2.062 .042 
AGE .021 .009 .193 2.194 .030 
 
The study showed that an increase in age, total cholesterol or random blood sugar 
by one unit will increase the MPV by 0.193, 0.183 and 0.355 respectively as 
evidenced by the beta coefficients 
 
 
RELATIONSHIP BETWEEN MPV AND OTHER PARAMETERS 
 The mean platelet volume is compared with several parameters. 
 
 
Age group comparisons 
 
The Mean platelet volume was found in different age groups and it was 
analysed with One way ANOVA to find any significant difference . The 
„p‟ value was found to be 0.114 and hence there was no significant 
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difference on comparing the mean platelet volume in all the age groups. 
Table – 9 summarises the mean and the standard deviation of the Mean 
platelet volume  in  the different age group . Table – 10 shows the results 
of the  One way ANOVA done to compare the different age groups and 
their mean platelet volume. 
Table – 9 ( Relationship between Age & MPV ) 
 
 
Age 
Group 
N Mean Std. 
Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
< 30 1 10.100000 . . . 
30 – 39 15 8.573333 1.3040961 7.851149 9.295518 
40 – 49 25 8.836000 1.4174155 8.250920 9.421080 
50 – 59 26 8.507692 1.6716275 7.832507 9.182877 
60 – 69 34 9.041176 1.1279151 8.647628 9.434725 
70 – 79 10 9.820000 .5865151 9.400432 10.239568 
Total 111 8.886486 1.3592435 8.630812 9.142161 
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 Table – 10 ( One way ANOVA results on age groups with MPV ) 
 Sum of Squares df Mean 
Square 
F Sig. 
(‘p’) 
Between 
Groups 
16.266 5 3.253 1.827 0.114 
Within Groups 186.964 105 1.781   
Total 203.230 110    
 
Group 2 = 30 – 39 years                                                                         df- degrees of freedom 
Group 3 = 40 – 49 years 
Group 4 = 50 – 59 years 
Group 5 = 60 – 69 years 
Group 6 = > 70 years 
 
 
The  „p‟ value was not found to be less than .05, showing no statistically 
significant difference between the age groups. The highest MPV was found in 
the age group between 70-79 years. 
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Figure – 3 ( Mean plot of the MPV in the different age groups ) 
 
 
Relationship between Sex and MPV 
 
The  MPV for males was  9.01±1.30and the MPV for females was 
8.59±1.45. On analysing the MPV with the two sex by Independent „t‟ 
test , the „p‟  value was not significant. Hence the MPV is not 
significantly different between the 2 sexes. Table – 11 shows the MPV in 
the 2 sex and the Table – 12 shows the result of the Independent „t‟ test. 
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Table – 11 ( MPV in the sex groups ) 
 SEX N Mean Std. Deviation Std. Error Mean 
MPV 
Males 77 9.014286 1.3059292 .1488244 
Females 34 8.597059 1.4513286 .2489008 
 
Table – 12 ( Independent „t‟ test results of sex groups with MPV ) 
 Levene's Test for 
Equality of Variances 
t-test for Equality of 
Means 
F Sig. t Df 
MPV 
Equal variances 
assumed 
.983 .324 1.499 109 
Equal variances not 
assumed 
  
1.439 57.616 
 
Relationship between smoking and MPV 
 
 The Mean platelet count was compared between Smokers and Non 
smokers. The number of smokers in MI , Unstable angina and Control 
groups were 22, 10 and 3 respectively. The number of non-smokers in 
MI, Unstable angina and Control groups were 23, 31 and 22 respectively. 
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Table – 13 shows the distribution of smokers and non-smokers in the 3 
groups. 
Table – 13 ( Smokers and Non- smokers in the 3 groups ) 
 Group 
MI Unstable 
Angina 
Control 
SMOKING 
Yes 22 10 3 
No 23 31 22 
 
The mean platelet volume was compared between the smokers and non 
smokers by independent „t‟ test and the „p‟ value was found to be not 
significant. The MPV among smokers was 9.41±1.19 and among non-
smokers it was 8.64±1.36. Table – 14 shows the MPV among smokers 
and non-smokers. Table – 15 shows the result of the Independent „t‟ test 
to compare the MPV between smokers and non-smokers. 
Table – 14 ( MPV among smokers and non-smokers ) 
 SMOKING N Mean Std. Deviation Std. Error 
Mean 
MPV 
Yes 35 9.414286 1.1936456 .2017629 
No 76 8.643421 1.3689252 .1570265 
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Table – 15 ( Results of Independent „t‟ test comparing smoking 
groups with MPV) 
 Levene's Test for 
Equality of Variances 
t-test for Equality 
of Means 
F Sig. t Df 
MPV 
Equal variances 
assumed 
2.162 .144 2.866 109 
Equal variances not 
assumed 
  
3.015 75.161 
 
Relationship between systemic hypertension & MPV 
 The number of hypertensives in MI, Unstable angina and Control groups 
were 28, 20 and 3 respectively. The number of non-hypertensives in MI, 
Unstable angina and Control groups were 17, 21 and 22 respectively. Table – 16 
shows the distribution of hypertensives and non – hypertensives in all the 3 
study groups. 
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Table – 16 ( Distribution of Hypertensives and Non-hypertensives) 
 
 Group 
MI Unstable 
Angina 
Control 
Hypertension 
Yes 28 20 3 
No 17 21 22 
 
 The MPV among hypertensives was 9.42±1.03 and among non-
hypertensives was 8.43±1.44. The MPV was compared among hypertensives 
and non-hypertensives by independent „t‟ test and the „p‟ value turned out to be 
significant. Table – 17 shows the MPV among  hypertensives and non-
hypertensives. Table – 18 shows the results of the Independent „t‟ test 
comparing MPV between hypertensives and non hypertensives. 
 
Table – 17 ( MPV among hypertensives and non-hypertensives) 
 
 
 Hypertension N Mean Std. Deviation Std. Error Mean 
MPV 
Yes 51 9.421569 1.0309828 .1443665 
No 60 8.431667 1.4442747 .1864551 
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Table – 18 ( Independent „t‟ test results comparing MPV among 
hypertensives and non-hypertensives ) 
 Levene's Test for Equality 
of Variances 
t-test for Equality of Means 
F Sig.(‘p’) T Df 
MPV 
Equal variances 
assumed 
14.078 .000 4.088 109 
Equal variances not 
assumed 
  
4.198 105.994 
 
Relationship between Diabetes Mellitus & MPV 
  The number of diabetics in MI, Unstable angina and the Control groups 
was 17, 10 and 6 respectively. The number of non-diabetics among MI, 
Unstable angina and control groups was 28, 31 and 19 respectively. Table – 19 
shows the distribution of diabetics and non diabetics in the 3 groups. 
Table – 19 ( Distribution of Diabetics and non diabetics ) 
 Group 
MI Unstable angina Control 
DIABETES 
Yes 17 10 6 
No 28 31 19 
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 The MPV among diabetics was 9.25±1.29 and among non-diabetics was 
8.73±1.36. The MPV was compared between diabetics and non diabetics using 
Independent „t‟ test and the „p‟ value turned out to be not significant. Table – 20 
shows the MPV among diabetics and non diabetics. Table 21 – shows the 
results of the independent „t‟ test done to compare MPV between diabetics and 
non-diabetics. 
Table – 20 ( MPV among Diabetics and Non-Diabetics ) 
 DIABETES N Mean Std. 
Deviation 
Std. Error Mean 
MPV 
Yes 33 9.254545 1.2968931 .2257601 
No 78 8.730769 1.3629902 .1543282 
 
 
 
Table – 21 ( Independent „t‟ test results comparing MPV between  Diabetics 
and Non Diabetics) 
 
 Levene's Test for Equality 
of Variances 
t-test for Equality of 
Means 
F Sig.(‘p’) t Df 
MPV 
Equal variances 
assumed 
.062 .804 1.877 109 
Equal variances not 
assumed 
  
1.915 63.163 
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Relationship between ejection fraction & MPV 
 
The Ejection fraction was divided into 4 groups ≤29, 30 – 39 , 40 – 49 and ≥50. 
The MPV in these groups was 10.7±0.25, 10.04±0.55, 9.83±0.61 and 9.44±0.67 
respectively. Table – 22 shows the MPV in all the different groups. 
 
Table – 22 ( Mean Platelet Volume among different Ejection Fraction 
Groups ) 
 
 
 N Mean Platelet 
Volume 
Std. Deviation Std. Error 
≤29 4 10.700000 .2581989 .1290994 
30 - 39 9 10.044444 .5525195 .1841732 
40 - 49 19 9.836842 .6130167 .1406357 
≥50 13 9.446154 .6703424 .1859195 
Total 45 9.842222 .6767197 .1008794 
 
\ 
 
 
 The mean platelet volume was compared in the 4 different groups by One 
way ANOVA and the „p‟ value turned out to be significant. Hence the mean 
platelet volume is significantly different in each of these groups and then on 
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seeing the mean platelet volumes in the different groups , it‟s clear that in 
patients with Ejection Fraction ≤29 , the mean platelet volume is the highest. 
Hence we can conclude mean platelet volume is significantly different and 
higher as the ejection fraction reduces. The Following Table – 23 shows the 
results of  One way ANOVA done to compare the MPV among the different 
ejection fraction groups.  
 
 
 
Table – 23 ( Results of One Way ANOVA after 
comparing the MPV in all the different Ejection Fraction 
groups ) 
 
 
 Sum of 
Squares 
Df Mean 
Square 
F Sig.(‘p’) 
Between Groups 5.351 3 1.784 4.942 .005 
Within Groups 14.799 41 .361   
Total 20.150 44    
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Figure – 4 ( Mean Platelet Volume Plots among the different 
Ejection Fraction Groups ) 
 
 
 
 
 
Group EF 1 = ≤29 
Group EF 2 = 30 – 39  
Group EF 3 = 40 – 49  
Group EF 4 = ≥50 
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Relationship between arrhythmias and MPV 
 
 The mean platelet volume among patients with arrhythmia was 9.83±0.44 
and among patients without arrhythmia was 9.84±0.72.  The mean platelet 
volume was compared in these 2 groups of patients by Independent „t‟ test and 
„p‟ value was found to be insignificant. Table – 24 shows the Mean Platelet 
Volume in the 2 groups of Patients with and without arrhythmia. Table 25 – 
shows the results of the Independent „t‟ test . 
Table – 24 ( Mean Platelet Volume among arrhythmics and Non 
arrhythmics ) 
 
 N Mean Std. Deviation Std. Error 
Arrhythmics 8 9.837500 .4405759 .1557671 
Non-Arrhythmics 37 9.843243 .7224728 .1187738 
Total 45 9.842222 .6767197 .1008794 
 
Table – 25 ( Results of Independent ‘t’ test comparing MPV between 
Arrhythmics and Non arrhythmics ) 
 
 Sum of 
Squares 
Df Mean Square F Sig.(‘p’) 
Between Groups .000 1 .000 .000 0.983 
Within Groups 20.150 43 .469   
Total 20.150 44    
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Figure – 5 ( MPV among Arrythmics and Non Arrhythmics ) 
 
1 – Arrhythmics 
2 – Non Arrhythmics 
Relationship between survival without complication and MPV 
 The MPV was compared among patients who survived without 
complications and those with complications. The mean was 9.62±0.71 and 
10.09±0.54 respectively. The 2 group of patients were compared with their 
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means by Independent „t‟ test and the „p‟ value came out to be significant. 
Hence the MPV in patients with Complications is significantly different and 
higher than the patients without complications. Table – 26 shows the MPV 
among the 2 groups of patients. Table – 27 shows the results of the Independent 
„t‟ test with the significant „p‟ value. 
Table – 26 ( MPV among patients who had complications and without 
complications ) 
 
 N Mean Std. Deviation Std. Error 
 without Complications 24 9.625000 .7133814 .1456184 
 With Complications 21 10.090476 .5485479 .1197030 
Total 45 9.842222 .6767197 .1008794 
 
Table – 27 ( Results of Independent „t‟ test comparing the MPV in patients 
who survived without complications and with complications ) 
 
 
 Sum of 
Squares 
df Mean Square F Sig.(‘p’) 
Between Groups 2.427 1 2.427 5.888 .020 
Within Groups 17.723 43 .412   
Total 20.150 44    
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Figure – 5 ( Mean Platelet Volume Plots among patients without 
complications and with Complications ) 
 
1 –  without Complications 
2 –  with Complications 
 
Relationship between occurrence of death and MPV : 
 The mean platelet count was compared among patients who died and 
those who did not . The mean was 10.53±0.35 and 9.73±0.65 respectively in the 
2 groups. The 2 groups were compared by Independent „t‟ test and the „p‟ value 
turned to be significant. Hence the MPV in patients who died is significantly 
different and higher than the patients who did not die. Table – 28 shows the 
mean platelet volume among the patients those who died and those who did not 
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.  Table – 29 shows the results of the Independent „t‟ test and the „p‟ value 
turned out to be significant . Hence the MPV among the patients who died is 
significantly different and higher than the patients who did not die 
. 
Table – 28 ( Mean Platelet Volume among patients who died and who did 
not 
 
Table – 29 ( Result of Independent „t‟ test comparing MPV in patients who 
died and those who did‟t ) 
 
 
 Sum of 
Squares 
df Mean Square Sig.(‘p’) 
Between Groups 3.307 1 3.307 .006 
Within Groups 16.843 43 .392  
Total 20.150 44   
     
 
 
 N Mean Std. Deviation Std. Error 
Patients who died 6 10.533333 .3502380 .1429841 
Patients who didn’t die 39 9.735897 .6535277 .1046482 
Total 45 9.842222 .6767197 .1008794 
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Figure – 6 ( MPV among patients who died and those who didn’t 
die) 
1 – Patients who died 
2 – Patients who did not die. 
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                                                     DISCUSSION 
 
                          Coronary artery disease is a major cause of morbidity and 
mortality in industrialized countries and is becoming a major problem in     
developing countries like India. The risk of acute coronary syndrome is   
significantly increased by the endogenous and exogenous risk factors like 
diabetes, systemic hypertension, smoking and hypercholesterolemia. The 
individual risk for myocardial infarction is also increased by these factors. 
However they only explain a part of the cases and there may be other relevant 
risk factors which need to be identified. The thrombogenic phase is started by 
the rupture of an atherosclerotic plaque. The platelets play an important role for 
the progression of the thrombus
49
. 
                                    The function and activation of platelets are directly 
indicated by its volume. The secretory granules and mitochondria in larger 
platelets are significantly higher and hence they are more active than smaller 
platelets .The larger platelets are hyperactive and leads to the formation and 
dissemination of intracoronary thrombus
12
.This may again accelerate the 
evolution of clinical state called as acute coronary syndrome
12
.  Van der Loo et 
al , in their study, claimed that platelet volume was an important biological 
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variable to determine platelet reactivity . They also suggested  that elevated 
platelet volume measured after MI might be a determinant factor for future 
ischemic episodes and death. In this study an attempt was made to find out if 
any association existed between the platelet size and acute coronary syndrome 
among Indian population as reports are scanty.  
         In this study the age of MI cases ranged from 28 to 78 years with 
mean age 55.18±12.881, unstable angina ranged from 30 to 80 years with mean 
age 53.73±13.504. This corresponds to the pattern reported in India. 
         In the present study there was no significant difference in MPV 
between the age groups . Funiak et al (1994), in their study, found that MPV 
was significantly increased in platelets of advanced age and was statistically 
significant
16
. Bancroft et al (2000) stated that MPV decreases with age
46
. The 
present study did not show any difference in MPV  between the age groups , but 
age was found to be a determinant factor for MPV on multiple linear regression 
analysis.  
           Among the 45 MI cases there were 33 males (73%) and 12 
females(26%). Among the 41 unstable angina group, there were 29 males (70%) 
and 12(30%) females. Before menopause, women have a lower age adjusted 
incidence and mortality for coronary heart disease than men. This suggest a 
major role for estrogen in delaying progression of atherosclerosis. This effect 
results from beneficial action of estrogen on lipid fractions. Estrogen reduces 
LDL-C by 10-15% while increasing HDL-C 
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Ridwan Mercan et al , in 2010 did a comparison study on MPV between 
MI, Unstable angina and control groups. They found out that MPV was 
significantly higher in MI and Unstable angina groups when compared to 
normal groups. They claimed that MPV was higher in acute coronary syndrome. 
In consistent with these findings, the present study also found out a high 
normal  MPV in MI and Unstable angina when compared to control groups.  
In the present study the Mean Platelet Volume in MI group is 9.84±0.67 and the 
values ranged from 8.6 to 11, in Unstable angina group mean MPV is 9.07±0.77 
and the values ranged from 7.0 to 10.6 and in the Control group mean platelet 
volume is 6.85±0.73 and the values ranged from 6.0 to 8.4. The MPV was 
found to significantly different between these three groups. The mean MPV was 
higher in MI group when compared to other groups. It was found to be 
statistically significant. The mean MPV in Unstable angina group was higher 
when compared to control group, while lower when compared to MI group. The 
difference was found to be statistically significant. 
                  Previous studies on MPV and acute coronary syndromes have 
given good correlations. Kishk et al. in their study, compared AMI patients to 
stable angina pectoris and control groups and detected that the former group had 
lower platelet count and higher MPV .  They suggested, based on their study, 
that higher MPV and decreased platelet count may be a major risk   factor for 
acute myocardial infarction
7
. In consistent with these findings, in present study  
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MPV was significantly higher and platelet count was lower in acute myocardial 
infarction group, compared to control groups 
                                      Puzzili et al. , in their study, found out that, unstable 
angina pectoris patients showed larger MPV, compared to stable angina and 
control groups 
11
. In that study, they also detected that MPV was higher in 
unstable angina pectoris subjects who required emergent angioplasty, compared 
to the rest of unstable angina pectoris patients. With all these evidence they 
claimed that  large volume platelets bestowed the formation of thrombus in 
coronary artery and led to reduction of platelet counts. In consistent with these 
findings, the present study showed that  MPV was  significantly higher and 
platelet count to be lower in unstable angina pectoris group than those in control 
groups. 
                                            Halbmayer et al (1995) stated that MPV did not 
differ significantly between MI patients and controls in their study. In contrast 
to this Cameron et al (1983) found an increased mean platelet volume among 
those with acute myocardial infarction compared to controls. Similar findings 
were observed by Martin et al(1983) in their study. Large platelets are denser, 
they produce more thromboxane A2 per unit volume of platelet cytoplasm. 
Larger platelets aggregate more rapidly upon collagen challenge, release more 
serotonin and other granule contents and express more receptors per unit area 
(Pizzuli et al). So an increased MPV , as an indicator of larger , more reactive 
platelets, may represent a risk factor for myocardial infarction(Endler et al).  
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                     The question arises whether the increase in platelet volume occurs 
before the  acute coronary event or does it occur as a response to the platelet 
consumption in ACS. Martin et al , who did a study on MPV in acute 
myocardial infarction , measured mean platelet volume within 12 hrs of 
admission to hospital and then later at 6 weeks. They stated that mean platelet 
volume was increased before the occurrence of MI and depicted the following 
explanations. The increase in platelet volume seen within the first 12 hrs of 
admission suggested that the increase was present before infarction, as the life 
span of platelet is about 8 days. More than 90% of the platelet population whose 
distribution was measured after MI were circulating before the vascular 
occlusion occurred. 
                            Further proof that the increase in MPV occurs before the 
myocardial infarction is got from the study conducted by Endler et al (2002). 
They evaluated mean platelet volume in patients presenting with acute 
myocardial infarction and in patients with history of previous myocardial 
infarction. They found out that MPV was significantly raised in those with acute 
MI. This further adds to the proof that raised MPV precedes the occurrence of 
MI. 
                 O‟Malley et al (1995) conducted a similar study of MPV estimation 
in stroke patients. They estimated MPV in stroke patients within 48 hrs of 
admission and also at 6 months later and compared it with controls. They found 
that MPV was significantly raised in stroke patients when compared to controls. 
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They suggested that the changes in MPV might have preceded the vascular 
event and is unlikely due to the platelet consumption at the infarct site. They 
said that since the average life span of platelets is about 8 days, the elevated 
MPV seen within the first 48 hrs after stroke represented platelets released 
before infarction. They also added that, the fact that the observed increase in 
MPV had remained unchanged in post stroke survivors was further evidence 
that changes in MPV were likely to have preceded the acute event. 
       The platelet counts in the study groups were compared. In the MI group the 
mean platelet count was 141800±63350 and the values ranged from 75000 to 
310000, in the Unstable angina group the mean was 138243±61436 and the 
values ranged from 80000 to 340000 and finally in the Control group the mean 
was 230800±56856 and the values ranged from 120000 to 340000. The mean 
platelet count was found to be significantly different all the three groups. The 
MI and unstable angina group had significantly lower platelet count when 
compared to the control group. This finding was correlating to the study 
conducted by Cameroon et al (1983) , as they noticed that the patients with 
acute MI had a reduced platelet count when compared to the control groups. 
They observed a reduced platelet count and increased MPV in patients with MI. 
The observation in our study runs parallel to the findings of above workers. 
                             In the present study MPV was independent of genders. The 
MPV for males was 9.01±1.30and the MPV for females was 8.59±1.45. The test 
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showed no statistical significant difference. This is in parallel with the 
observation made by Bancroft et al (2000). 
                               The Mean platelet count was compared between Smokers 
and Non smokers. The number of smokers in MI , Unstable angina and Control 
groups were 22, 10 and 3 respectively. The number of non-smokers in MI, 
Unstable angina and Control groups were 23, 31 and 22 respectively .The Mean 
platelet volume was compared between the smokers and non smokers by 
independent „t‟ test and the „p‟ value was found to be not significant. The MPV 
among smokers was 9.41±1.19 and among non-smokers it was 8.64±1.36.  The 
study showed an increased prevalence of smoking habit among those with acute 
coronary syndrome. Although the mean MPV was higher among smokers 
compared to non smokers, the relationship was not statistically significant. 
Tschope et al(1989) and Kario et al(1985) in separate studies found smokers to 
have an increased MPV.  Kishk et al (1985) observed no relation between 
smoking and MPV. Matsuo et al (1992) found out a significant increase in MPV 
among elderly smokers.  They claimed that the increase in MPV due to smoking 
will also contribute to the formation of atherosclerotic plaque. However the 
present study did not show any statistical correlation. Larger sample size may 
be needed for establishing such correlations. 
                                     The relationship between MPV and systemic 
hypertension was studied. The number of hypertensives in MI, Unstable angina 
and Control groups were 28, 20 and 3 respectively. The number of non-
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hypertensive in MI, Unstable angina and Control groups were 17, 21 and 22 
respectively. The MPV among hypertensive was 9.42±1.03 and among non-
hypertensive was 8.43±1.44. The MPV was compared among hypertensive and 
non-hypertensive by independent„t‟ test and the „p‟ value turned out to be 
significant. Osuna et al (1998) also observed a higher MPV in those with 
systemic hypertension. Erkan coban et al (2005) in their study found out that 
MPV was significantly higher among patients with essential hypertension .Hyan 
ah chang et al (2010), in their study, found out  that MPV is significantly raised 
in systemic hypertension. The present study, like the above mentioned works, 
showed similar correlation between systemic hypertension and MPV. Ntaios G 
et al (2011) studied the significance of MPV in stroke and even proved that 
systemic hypertension is an independent predictor of MPV . 
              The relationship between MPV and diabetes mellitus was studied.  The 
number of diabetics in MI, Unstable angina and the Control groups was 17, 10 
and 6 respectively. The number of non-diabetics among MI, Unstable angina 
and control groups was 28, 31 and 19 respectively. The MPV among diabetics 
was 9.25±1.29 and among non-diabetics was 8.73±1.36. The MPV was 
compared between diabetics and non diabetics using Independent„t‟ test and the 
„p‟ value turned out to be not significant.  On doing multiple linear regression 
analysis, random blood sugar was found to determine the MPV. This study 
showed that as the random blood sugar increases by 1, the MPV gets raised by 
0.193. Sharpe et al (1993) showed that MPV was significantly increased in 
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diabetic subjects when compared to non-diabetics. They stated that since the 
platelet size is a determinant of platelet function, with larger platelets being 
more reactive per unit volume, platelets might play a part in the micro and 
macro vascular complications of diabetes mellitus. The fact that in our study, no 
relationship was observed, may be due to the small sample size.  
                                ROC curve analysis was done in this study to compare the 
mean platelet volume with a standard diagnostic test like Trop-T  and  assess the 
Sensitivity and Specificity of Mean platelet Volume in detecting MI. The cut off 
value was found to be 8.8fl with a sensitivity of 91.11% and specificity of 
62.12%. Guisseppe lippe et al (2009) , in their study found the cut off of MPV 
as 9.0 fl with negative and positive predictive value of 83% and 43% 
respectively. They suggested that as MPV is a simple and inexpensive 
laboratory measurement, it might be considered a useful rule-out test, along 
with other conventional cardiac biomarkers for the risk stratification of acute 
coronary syndrome patients admitted to the emergency departments. 
                                     Mean platelet volume and its relation to various outcome 
within 7 days after admission was studied to determine its prognostic 
significance. The various outcomes studied were ejection fraction, arrhythmias , 
cardiac failure and death. The Ejection fraction was divided into 4 groups ≤29, 
30 – 39 , 40 – 49 and ≥50. The MPV in these groups was 10.7±0.25, 
10.04±0.55, 9.83±0.61 and 9.44±0.67 respectively. The  mean platelet volume 
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was significantly different and higher as the Ejection Fraction reduces. The 
highest MPV was obtained in ejection fraction ≤29. Hendra et al (1998) stated 
that all patients with severe cardiac failure had larger platelet volumes than 
patients with mild or no failure. Osuna et al(1998) also observed that an 
increased platelet volume was related to a higher risk of cardiac failure. The 
present study also showed a significant relation between MPV and ejection 
fraction. 
                        The Mean Platelet Volume  among  patients with arrhythmia was 
9.83±0.44 and among patients without arrhythmia was 9.84±0.72. There was no 
significant difference between the two groups. Yucel colkesen et al in 2007, 
found out that MPV is significantly raised in patients with paroxysmal atrial 
fibrillation. However the present study did not show any statistical correlation 
between arrhythmia and MPV. The MPV was compared among patients who 
survived without complications and those with complications. The mean was 
9.62±0.71 and 10.09±0.54 respectively. The MPV in patients with complication 
was found to be significantly different and higher than that of the patients 
without complications. Tagleri N , Saia F et al in 2011, in their study found out 
that higher MPV during the admission time was associated with complications 
in acute coronary syndrome. They claimed that MPV could be used as an 
important tool for risk stratification in acute coronary events. Rosa A Lopez et 
al in 2012 , in their study ,concluded that elevated MPV determined in the first 
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24hrs following admission was associated with a poorer in- hospital prognosis 
due to an increase in mortality. In the present study also elevated MPV was 
associated with an increased incidence of complications. The Mean Platelet 
count was compared among patients who died and those who did not . The 
mean was 10.53±0.35 and 9.73±0.65 respectively in the 2 groups. The MPV in 
patients who died was significantly different and higher than the patients who 
did not die. Thus similar to the observations of Rosa A Lopez et al, the present 
study also showed an increased mortality associated with higher MPV. The 
same observations were made by Hendra J et al(1998), Osuna et al (1998) and 
Martin et al (1991). 
LIMITATIONS OF THE STUDY 
1. Serial monitoring of increase in MPV was not assessed. 
This might have given a better insight into the nature of progression in 
those who developed complications. 
2. The follow up period was only seven days.  Prolonged follow up analysis 
might have resulted in a valid conclusion regarding prognostic 
implications 
3. Economical constraints has led to the limited sample size. Future studies 
with larger sample size are needed. 
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                                           CONCLUSION 
 
 MPV was significantly elevated in Myocardial infarction group  
 
(9.84±0.67 fl) when compared to Unstable angina (9.07±0.77fl)  and  
 
control groups( 6.85±0.73fl) 
 
 In the MI group the mean platelet count was 141800±63350 and the 
 
 values ranged from 75000 to 310000, in the Unstable angina group the  
 
mean was 138243±61436 and the values ranged from 80000 to 340000  
 
and finally in the Control group the mean was 230800±56856 and the  
 
values ranged from 120000 to 340000. Platelet count was significantly  
 
lower in MI and unstable angina group when compared to control  
 
group. 
 
 MPV  of  8.8 fl has   91.11% sensitivity and 62.12% specificity in 
detecting MI when compared to Trop –T 
 No significant difference was observed in MPV between the age 
groups, but  MPV was found to increase by 0.193 as age advances by 
1yr as evidenced  by β coefficient for age multiple linear regression 
analysis. 
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 MPV was found to be gender independent 
 MPV in acute coronary syndrome was found to be independent of 
smoking  and diabetes mellitus. 
 The study showed that an increase in age, total cholesterol or random 
blood sugar by one unit will increase the MPV by 0.193, 0.183 and 
0.355 respectively as evidenced by the beta coefficients 
 MPV was found to be significantly elevated in hypertensives 
(9.42±1.03fl), when compared to non- hypertensives(8.43±1.44fl) 
 MPV was found to influence the short term outcome after MI  
                The  MPV in patients with  Complications(10.09±0.54 fl) was      
significantly different and higher than the patients without 
complications(9.62±0.71fl). So patients with higher MPV may be 
expected to manifest with  complications in MI 
 MPV was significantly elevated in patients with 
                    lower ejection  fraction. So a higher admission time MPV,  
                   can  predict a lower ejection fraction in MI . 
 MPV was not related to the occurrence of  arrhythmia in MI 
 The MPV in patients who died(10.53±0.35 fl) was significantly 
different and higher than the patients who did not die. Hence larger 
MPV was found to predict the mortality 
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 ANNEXURE I                                   
                PROFORMA 
   
 Case No         : 
 Name             :                                       Occupation: 
 Age                :                                        IP No         : 
 Sex                 : 
 Date Of Admission           :                     
 Date Of Discharge / Death: 
HISTORY 
Time of onset of chest pain: 
Time of admission             : 
Previous MI                       : Yes/ No 
Previous Unstable angina  : Yes/ No 
Smoking                             :Yes/ No 
Systemic Hypertension      : Yes/No, if Yes , under regular treatment ? Yes/ No 
Diabetes mellitus                :Yes/No, if Yes , under regular treatment ? Yes/ No 
EXAMINATION 
Pulse:              
Blood pressure: 
S3        : Yes/ No                                
JVP  elevation: Yes/No                    Killip class:  I       II       III        IV 
Basal crackles : Yes/ No 
 
INVESTIGATIONS: 
Blood sugar                :                                             Hb:       TC:              DC: 
Blood urea                  :                                             ESR: 
Serum creatinine         :                                            Peripheral smear: 
Serum Total cholesterol :                                                         Others: 
Troponin T card test     : Positive / Negative 
Mean platelet Volume  : 
Platelet count                : 
ECG                              : 
 
ECHO                         
1.  RWMA                     : Yes/ No, if yes which wall? 
2. Ejection fraction        : 
3. Diastolic dysfunction : 
4. Clot                            : 
Diagnosis       :  
OUTCOME 
Survived without complications: 
 with complications     :     
Death 
 
  
 
 
 
 
 
 
 
 
                      MASTER CHART 
 
 
 
 
S.No NAME SEX AGE MI   DM HTN SMOKING  RBS T.Chol MPV Platelet 
count 
Arrhythmia Death EF No  
compl 
1 Ganeshan 1 78 1 2 1 1 136 184 10.3 100000 2 2 50 1 
2 kuppusamy 1 57 1 1 2 2 238 220 9.6 90000 1 2 40 2 
3 Thankamani 1 45 1 2 1 2 126 188 10.4 120000 2 2 40 1 
4 Arumugham 1 45 1 2 2 1 130 150 9.6 100000 2 2 54 1 
5 vasu 1 47 1 2 1 1 110 240 11 88000 2 2 40 1 
6 Abdul latheef 1 63 1 1 2 1 310 178 10.1 88000 2 2 40 1 
7 Thomas 1 67 1 2 1 1 130 180 8.8 140000 2 2 65 1 
8 Kanagambika 2 72 1 1 1 2 240 200 10.2 80000 2 2 36 2 
9 Perumal 2 65 1 1 1 2 190 168 10 90000 2 1 30 2 
10 Murugaiyyan 1 63 1 1 1 1 240 177 10.1 120000 2 2 30 2 
11 krishnamoorthy 1 60 1 2 1 1 130 140 8.6 130000 2 2 50 1 
12 Amsammal 2 78 1 2 2 2 140 150 8.9 100000 2 2 36 2 
13 Arumugham 1 60 1 2 1 2 120 170 10 120000 1 2 40 2 
14 Joseph 1 55 1 2 2 1 140 180 10.4 80000 2 2 40 1 
15 Sellachi 2 50 1 1 2 2 190 240 10 80000 2 2 30 2 
16 Ramani 2 64 1 2 1 2 140 220 8.6 100000 2 2 46 1 
17 Kannan 1 52 1 2 1 1 130 200 10.4 75000 2 1 20 2 
18 Thyagarajan 1 57 1 2 2 1 102 200 9 80000 2 2 46 1 
19 Arokyasamy 1 65 1 2 1 1 110 156 10.2 200000 2 2 40 1 
20 Chandravel 1 35 1 1 1 2 180 190 9.8 300000 2 2 56 1 
21 Chelladurai 1 40 1 2 2 1 120 160 10.6 310000 2 2 52 1 
22 Sundaram 1 60 1 1 2 2 210 226 11 120000 2 2 36 2 
23 Mohammed 
sharif 
1 48 1 2 1 1 130 240 10.1 140000 2 2 46 1 
24 Muthuraja 1 30 1 2 1 1 120 230 9 180000 2 2 50 1 
25 Karuppaiyya 1 30 1 1 1 1 140 200 10.6 90000 2 1 20 2 
26 Uthrapathi 1 42 1 2 1 2 136 190 9 200000 2 2 56 1 
MYOCARDIAL INFARCTION GROUP 
SEX- 1 Male, 2 Female                                                                                                                                                       
Other variables                                                                                                                                                                        
      1 yes, 2 No                                                                                                                                                                  
                                                                                                                                                                                                 
                                                                                                                                                                           
27 Sahayaraj 1 50 1 2 1 1 140 156 9.4 160000 2 2 40 1 
28 Anbazhagan 1 60 1 1 1 2 166 210 10.4 100000 2 2 40 2 
29 Joseph raj 1 72 1 1 1 2 170 190 9.8 240000 2 2 44 2 
30 Ranganathan 1 62 1 1 1 2 180 190 9.8 90000 1 2 34 2 
31 Elangovan 1 33 1 2 1 2 130 200 9 200000 2 2 44 1 
32 Mariyammal 2 58 1 1 2 2 260 220 10.2 100000 1 2 40 2 
33 Vembu 2 28 1 2 2 2 130 240 10.1 200000 2 2 66 1 
34 Pankajam 2 75 1 2 1 2 130 180 11 100000 2 1 26 2 
35 Anjammal 2 65 1 1 1 2 140 160 10 100000 2 2 40 1 
36 Devaki 2 65 1 2 2 2 120 150 9 200000 2 2 46 1 
37 Asokan 1 40 1 2 1 1 110 190 9.4 100000 2 2 70 1 
38 Paulraj 1 53 1 2 1 1 130 190 10.4 120000 1 1 36 2 
39 Shakthi 2 40 1 1 2 2 268 200 10.8 200000 2 1 24 2 
40 Thambaiyya 1 69 1 2 2 1 146 186 10 200000 2 2 72 1 
41 Vasantha 2 60 1 1 2 2 190 212 9.6 150000 1 2 44 2 
42 Nagendran 1 58 1 1 1 1 230 180 10.1 100000 1 2 40 2 
43 Kunjuppillai 1 60 1 2 2 2 140 160 8.6 200000 2 2 76 1 
44 Shakthi 1 55 1 2 2 1 136 200 10 300000 2 2 38 2 
45 Govindasamy 1 52 1 2 1 1 120 190 9 200000 1 2 64 2 
UNSTABLE ANGINA GROUP 
S.No NAME SEX AGE UNSTABLE 
ANGINA 
DM HYPERTENSION SMOKING  RBS T.Chol MPV PLATELET 
COUNT 
1 gopalasamy 1 76 1 2 1 1 140 210 9.6 90000 
2 veeraguru 1 50 1 2 2 1 130 186 7 240000 
3 Ramakaya 1 67 1 1 2 2 176 200 8.8 240000 
4 Anjam 1 48 1 2 1 2 120 210 8.8 200000 
5 venkitachalam 1 60 1 2 1 2 110 190 9.6 100000 
6 Muthaiyya 1 40 1 2 1 2 120 186 9.8 200000 
7 Boss 1 52 1 1 2 2 186 200 10.4 110000 
8 Thavapandiyan 1 42 1 2 1 1 136 190 10.6 140000 
9 Ramalingam 1 35 1 2 2 2 120 160 7.8 340000 
10 povaliyan 1 55 1 2 1 1 140 210 9.6 90000 
11 palanimuthu 1 37 1 2 2 2 110 180 8.8 260000 
12 Appaviraja 1 65 1 2 1 2 120 180 9.1 200000 
13 Mohamed 
ismail 
1 71 1 1 2 2 178 200 10 100000 
14 Arokyasamy 1 62 1 2 1 2 110 240 10 100000 
15 Rajandran 1 55 1 2 2 2 86 170 9.2 90000 
16 Muthukrishnan 1 60 1 2 2 2 90 160 9 88000 
17 George 1 39 1 2 1 1 110 240 8.8 140000 
18 Muthaiyan 1 49 1 2 2 2 126 200 7.8 280000 
19 Durairaj 1 32 1 2 2 2 130 188 9.4 100000 
20 Nazeemudheen 1 45 1 2 2 2 140 190 8.8 120000 
21 Sreenivasan 1 50 1 1 1 1 220 240 9 130000 
22 Lenin Raj 1 65 1 2 1 1 130 190 8.6 120000 
23 Kam Raj 1 45 1 2 2 2 140 196 8 140000 
24 Malayan 1 40 1 2 1 1 110 200 10 100000 
25 Arumugham 1 60 1 2 2 1 120 188 10 120000 
26 Subramanyan 1 30 1 2 2 2 110 190 9.8 100000 
27 Sathyamoorthy 1 80 1 2 1 1 110 170 9.6 100000 
28 Muthu 1 64 1 2 2 2 120 180 8.8 160000 
29 Sekhar 1 40 1 1 1 2 230 200 9 100000 
30 Rajeshwari 2 77 1 2 1 2 130 196 9.4 90000 
31 Rukmini 2 64 1 2 1 2 140 190 9 200000 
32 Annapoorna 2 38 1 1 2 2 240 200 9.6 100000 
33 Duraiyammal 2 70 1 1 2 2 270 200 9.4 110000 
34 Lakshmi 2 35 1 1 2 2 190 210 9 160000 
35 Sumathy 2 40 1 2 1 2 110 200 8.8 100000 
36 Dhanalakshmi 2 65 1 1 2 2 130 170 8.1 80000 
37 Thaiyyal nayaki 2 55 1 2 1 2 126 188 8.6 100000 
38 Yasodhai 2 50 1 1 2 2 100 160 7.4 120000 
39 Dhanakodi 2 60 1 2 2 2 128 170 8.8 90000 
40 Palani 2 67 1 2 1 2 110 180 9 100000 
41 Neelamagham 2 68 1 2 1 2 126 270 9.4 120000 
 
 
       SEX- 1 Male, 2 Female                                                                                                                                                       
      Other variables                                                                                                                                                                        
      1 yes, 2 No                                                                                                                                                                  
 
 
 
CONTROL GROUP 
S.No NAME SEX AGE DIABETES  Hypertension SMOKING  SUGAR CHOLESTEROL MPV PLATELET 
COUNT 
1 selvi 2 40 2 2 2 125 160 6 240000 
2 pavanambal 2 45 1 2 2 165 160 7.8 300000 
3 ramu 1 68 2 2 2 125 178 7 300000 
4 raghav 1 40 2 2 2 140 180 8 200000 
5 anbujam 2 55 2 1 1 135 168 6 200000 
6 veeraiyyan 1 54 2 1 1 136 169 6.6 210000 
7 kumar 1 37 2 2 2 146 230 6.5 120000 
8 kaviyarasu 1 45 2 2 2 120 160 6.2 230000 
9 kathirvel 1 41 2 2 2 100 190 7 300000 
10 nageenthran 1 42 1 2 2 130 188 8.4 340000 
11 kala 2 55 2 2 2 120 156 6 310000 
12 jaffer 1 66 1 1 2 145 169 6.2 200000 
13 noorbeevi 2 56 2 2 2 140 166 6.4 210000 
14 kasthuri 2 33 1 2 2 160 188 6.6 150000 
15 kathirvel 1 32 2 2 2 136 182 7.3 160000 
16 lakshmi 2 66 1 2 2 180 163 7 190000 
17 thirunavakarasu 1 58 2 2 2 120 194 8.1 230000 
18 pushparaj 1 60 2 2 2 130 168 7.2 240000 
19 maithili 2 35 1 2 2 180 166 6.6 200000 
20 munusamy 1 50 2 2 2 98 172 6 190000 
21 venugopal 1 51 2 2 2 90 178 6.1 200000 
22 sardar 1 52 2 2 2 136 174 6.3 240000 
23 manu 1 60 2 2 1 130 165 7 200000 
24 pichaiyammal 2 44 2 2 2 120 176 7 300000 
25 fathima 2 45 2 2 2 130 180 8 310000 
 
 ANNEXURE III 
ABBREVIATIONS 
 
ACS      -   Acute Coronary Syndrome 
LDL      - Low Density Lipoprotein 
MPV     - Mean Platelet Volume 
HDL      - High Density Lipoprotein 
NO        - Nitric Oxide 
PF4       - Platelet Factor 4 
ADP     - Adenosine Di Phosphate 
ATP      - Adenosine Tri Phosphate 
GTP      - Guanosine Tri Phosphate 
TXA2   - Thromboxane A2 
STEMI- ST Elevation Myocardial Infarction 
MI        - Myocardial Infarction 
ECG     - Electro Cardio Gram 
Std.       - Standard 
Sig.       - Significance 
TGF      - Transforming Growth  Factor 
Df         - Degree of Freedom 
DM       -Diabetes Mellitus 
HTN     - Hypertension 
RBS     - Random Blood Sugar 
T. Chol  - Total Cholesterol 
EF          - Ejection Fraction 
No Comp- No Complication 
 
 
 
 
 
 
 
  
